BiotechTube

Acellular pertussis vaccine + Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) + Licensed TdaP booster vaccine + Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pertussis

Conditions

Pertussis, Whooping Cough, Tetanus, Lockjaw, Diphtheria

Trial Timeline

Mar 1, 2012 → Jul 1, 2013

NCT ID
NCT01529645

About Acellular pertussis vaccine + Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) + Licensed TdaP booster vaccine + Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)

Acellular pertussis vaccine + Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) + Licensed TdaP booster vaccine + Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) is a phase 1 stage product being developed by Novartis for Pertussis. The current trial status is completed. This product is registered under clinical trial identifier NCT01529645. Target conditions include Pertussis, Whooping Cough, Tetanus.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01529645Phase 1Completed

Competing Products

16 competing products in Pertussis

See all competitors
ProductCompanyStageHype Score
Adacel®SanofiApproved
84
aP booster + TdaP booster + Licensed TdaP booster (Boostrix®)NovartisPhase 1
33
Boostrix + Placebo (Saline)NovartisApproved
85
Tetanus Toxoid, acellular pertussis, diphtheria toxoidSanofiPre-clinical
22
ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed + BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis AdsorbedSanofiApproved
84
COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)SanofiApproved
84
(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular PertussisSanofiPhase 1/2
40
DT5aP-IPV-Hib 5-component Pertussis vaccine + Infanrix® -IPV+HibSanofiPhase 3
76
Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV + Hepatitis B vaccineSanofiPhase 2
51
DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus) + DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b) + Inactivated Poliomyelitis Vaccine + Poliomyelitis Vaccine bivalent types 1 and 3 + Human Rotavirus, live attenuated + Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)SanofiPhase 3
76
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis VaccineSanofiApproved
84
Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®) + Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)SanofiApproved
84
Pentacel® (DTaP-IPV/Hib) + Other Pertussis VaccinesSanofiPre-clinical
22
DTaP-IPV combined vaccine + DTaP vaccineSanofiPhase 3
76
ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed + DECAVAC®: Tetanus and Diphtheria Toxoids AdsorbedSanofiApproved
84
Tetanus and diphtheria toxoids and acellular pertussisSanofiPre-clinical
22

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85